Medtronic Up on Positive Preclinical Drug-Filled Stent Results - Analyst Blog

In an attempt to expand its interventional cardiology products portfolio, Medtronic plcMDT recently revealed preclinical outcomes of its latest, groundbreaking Drug-Filled Stent (DFS), demonstrating the device's safety and efficiency, at the 64 th Annual Scientific Session of the American College of Cardiology (ACC).

Following the news release, shares of this medical technology giant have risen 1.5% to eventually close at $77.61 yesterday.

The preclinical results validated Medtronic's DFS as a unique, next-generation stent device that allows controlled yet effective, polymer free drug elution over a desired period of time, directly into the arterial wall of coronary heart patients. The device was also found to minimize the chance of any diameter stenosis event and rapidly achieve complete stent coverage, accompanied by zero inflammation and adverse vascular responses.

Buoyed by the positive data, management plans to start a clinical trial - a first of its kind - involving the study of Medtronic's novel DFS, over the coming months. This 100-patient global study will analyze late lumen loss utilizing quantitative coronary angiography, at multiple sites in Australia and Brazil.

According to management, physicians face multiple complications while treating coronary patients with both bioabsorbable polymers and polymer-free technologies. Medtronic's primary purpose behind developing the novel internally-loaded DFS was to address these issues.

Management was pleased to declare that the preclinical outcomes confirm the ability of the polymer-free DFS to control drug release by eliminating any possibility of inflammation caused by polymer degradation.

Evidently, second-generation drug eluting stent (DES) technologies have delivered clinically superior outcomes in comparison to first generation DES in a broad spectrum of patient anatomies. Controlled polymer-free drug elution allows further optimized treatment option, both in the short and the long run.

Remarkably, Medtronic's DFS is based on the proven platform of Medtronic's first generation Resolute Integrity DES and the second-generation Resolute Onyx DES that incorporates the CoreWire Technology - which offers advanced visibility during the stenting procedure.

Currently, Medtronic's DFS is available for investigational use only and has not been approved for commercial use.

In the third quarter of fiscal 2015, Medtronic launched its second-generation Resolute Onyx DES in the international market. The device is seeks to provide improved drug deliverability without compromising radial and longitudinal strength, thus enhancing the efficiency of stenting procedures.

We believe the aforementioned news adds yet another milestone to Medtronic's ever-expanding interventional cardiology portfolio. We expect this development to help expand the company's shares in the global coronary stent market, which, according to CNBC, is expected to grow at a CAGR of 4.54% over the period 2013-2018.

Currently, the stock carries a Zacks Rank #2 (Buy). Some other top-ranked medical products stocks are Abaxis, Inc. ABAX , LeMaitre Vascular, Inc. LMAT and Phibro Animal Health Corp. PAHC . All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDTRONIC (MDT): Free Stock Analysis Report

ABAXIS INC (ABAX): Free Stock Analysis Report

LEMAITRE VASCLR (LMAT): Free Stock Analysis Report

PHIBRO ANIMAL (PAHC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos